<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) arising from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) shows different clinical features from de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the prognostic significance of immunophenotypic markers in patients with s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> arising from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Sixty-five adults diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> arising from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> between 1996 and 2010 were retrospectively analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>Immunophenotyping was performed for markers including CD3, CD7, CD10, CD13, CD14, CD19, CD33, CD34, CD41, CD45, CD56, CD65, CD117, HLA-DR, and TdT </plain></SENT>
<SENT sid="4" pm="."><plain>Of these immunophenotypic markers, only CD14 positivity was significantly associated with lower complete remission rate (P = 0.034) and significantly shorter overall survival (OS, P &lt; 0.001) and event-free survival (EFS, P &lt; 0.001) on univariate analysis </plain></SENT>
<SENT sid="5" pm="."><plain>On multivariate analysis, these differences remained significant in terms of OS [hazard ratio (HR) 4.49; P &lt; 0.001] and EFS (HR 4.06; P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Other significant prognostic variables included age ≥60 years [shorter OS (P = 0.003) and EFS (P = 0.020)], higher WBC count (&gt;60,000/μL) [shorter OS (P &lt; 0.001) and EFS (P = 0.001)], and poor cytogenetic risk group [shorter OS (P = 0.005)] </plain></SENT>
<SENT sid="7" pm="."><plain>CD14 expression on leukemic blasts is an independent prognostic factor for survival outcomes in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> arising from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>